Our Commitment to Therapy Education for Healthcare Providers
MDMA-assisted therapy has not been approved by any regulatory agency. The safety and efficacy of MDMA-assisted therapy have not been established for the treatment of PTSD.
At MAPS PBC, we have a long history of supporting qualified healthcare providers seeking to deliver investigational MDMA-assisted therapy in clinical trials for people with post-traumatic stress disorder (PTSD) and other mental health conditions. We have worked hard to provide a space for learning and exploration of this exciting new field of study and are grateful for the skilled and dedicated clinicians, educators and clinical trial sites who have come along this journey with us.
With our Phase 3 clinical trials now complete, we are moving into the next phase of our work. We plan to begin focusing our efforts on designing a therapy training program, in the event of U.S. Food and Drug Administration (FDA) approval. Given that focus, we will not be able to offer educational events in 2024.
This is an exciting time in the field of psychedelic medicine. The 30+ year journey to develop a clinical trial program for investigational MDMA-assisted therapy has required collaboration, learning, listening, patience, and the support of our community. We hope you will continue to collaborate with us to develop new psychedelic therapies for people in need.